CLEOPATRA Trial changes Std therapy Mets HER2 Positive BC

cp418

http://www.practiceupdate.com/news/6087

CLEOPATRA Trial Changes Standard Therapy for Metastatic HER2 Positive Breast Cancer

Successful targeting of the HER2 oncogene with trastuzumab plus chemotherapy converted HER2+ breast cancer from the worst prognosis to the best. Updated survival rests of CLEOPATRA, adding pertuzumab to docetaxel and trastuzumab, improved median OS by 16 months, more than the PFS was increased by dual anti- HER2 antibody therapy. This huge step forward confirms the power of dual blockade early in the treatment of HER2+ metastatic breast cancer.

SelenaWolf

Sweet!